Louise Grochow, MD, FACP is Executive Director of Global Medical Science, AstraZeneca. Dr. Grochow has more than 25 years experience in cancer drug development in academic, government and industry positions. She was a faculty member in the Departments of Oncology and Pharmacology at Johns Hopkins for 20 years; her research areas are clinical pharmacology, translational endpoints and early trials, including phase I trials of new treatments for cancer, phase II trials in colorectal and pancreatic cancer, and pharmacology studies in bone marrow transplantation. She performed the first time in man trials for such widely used drugs as paclitaxel, irinotecan, and topotecan and was pioneering in incorporating translational endpoints in early clinical trials at Hopkins and NCI. At NCI she also introduced the first studies of combinations of two agents while both were still investigation She was director of the GI Oncology Clinic, Associate Director of the Johns Hopkins General Clinical Research Unit, and Interim Director of the Division of Experimental Therapeutics at Johns Hopkins. In 1999, she moved to the National Cancer Institute as Chief of the Investigational Drug Branch, overseeing the development of more than 160 new treatments for cancer around the country in more than 400 trials each year, including grants supporting translational research associated with drug development. She joined AstraZeneca in 2005, where she is Executive Director of the Clinical-Discovery Team, directing the early development program for small molecules and antibodies , responsible for ensuring that clinical input is available from the time of target selection, and for incorporating translational endpoints, patient selection tools, and suitable biomarkers in AZ oncology trials of more than 40 small molecules.
She has published more than 120 peer reviewed articles, textbook chapters and reference books, and continues to serve on peer review panels for the National Cancer Institute as well as editorial boards for specialty journals, and to teach in ASCO and AACR seminars.
She was an undergraduate at MIT in Course 6, received her MD from Johns Hopkins University School of Medicine, completed medical residency at Georgetown University and the University of Chicago, and fellowships in medical oncology and clinical pharmacology at Johns Hopkins.
Executive Director
Global Medical Science
AstraZeneca
